AustralieFrV1, PascalFrancis, Corpus, bibRecord, 005302

Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission

Identifieur interne : 005302 ( PascalFrancis/Corpus ); précédent : 005301; suivant : 005303

Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission

Auteurs : Franco Locatelli ; Myriam Labopin ; Juan Ortega Giovanna Meloni ; Giorgio Dini ; Chiara Messina ; Isaac Yaniv ; Franca Fagioli ; Victoria Castel ; Peter J. Shaw ; Augustin Ferrant ; Andrea Pession ; Gerard Socie ; Francesco Frassoni

Source :

Blood [ 0006-4971 ] ; 2003.

RBID : Pascal:03-0346488

Descripteurs français

Pascal (Inist)
- Autogreffe, Greffe, Leucémie myéloblastique, Etude longitudinale, Europe, Pronostic, Incidence, Long terme, Complication, Etude multicentrique, Enfant, Cellule hématopoïétique, Cellule souche, Rémission, Santé publique.

English descriptors

KwdEn :
- Acute myelocytic leukemia, Autograft, Child, Complication, Europe, Follow up study, Graft, Hematopoietic cell, Incidence, Long term, Multicenter study, Prognosis, Public health, Remission, Stem cell.

Abstract

To evaluate factors influencing outcome and incidence of long-term complications, we analyzed, in a retrospective, multicenter study, 387 children who underwent autologous hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) in first complete remission (CR). Median follow-up time from transplantation was 60 months. Transplantation of bone marrow cells was performed in 318 children, whereas in 60 patients peripheral blood progenitor cells (PBPCs) were used. In multivariate analysis, we investigated the variables influencing probability of hematopoietic recovery, transplantation-related mortality (TRM), relapse, and leukemia-free survival (LFS). We found that use of PBPCs as stem cell sources and use of BCNU (N,N-bis[2-chloroethyl]-N-nitrosourea), amsacrine, VP-16, and cytosine arabinoside (BAVC) as a preparative regimen were associated with faster neutrophil recovery. Infusion of PBPCs, young age of patients, use of BAVCs, and absence of marrow purging predicted an accelerated platelet reconstitution. The 5-year Kaplan-Meler estimates of TRM, relapse, and LFS were 3% ± 1%, 39% ± 3% and 60% ± 3%, respectively. Relapse probability was increased in children given the BAVC regimen, and it was decreased after In vitro purging of hematopoietic progenitors and in children with a French-American-British classification of M3 and a time Interval of 170 days or more between CR and HSCT. These 2 latter variables favorably Influenced the probability of LFS, which was, by contrast, reduced with the BAVC regimen. Thirty-three percent of patients surviving more than 18 months experienced at least one late sequela; use of total body irradiation was the only predictive factor. The results obtained in this analysis can be of help in designing prospective studies of autologous HSCT in children with AML in first CR.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0006-4971`
A03		`1`		`@0 Blood`
A05				`@2 101`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission`
A11	`01`	`1`		`@1 LOCATELLI (Franco)`
A11	`02`	`1`		`@1 LABOPIN (Myriam)`
A11	`03`	`1`		`@1 GIOVANNA MELONI (Juan Ortega)`
A11	`04`	`1`		`@1 DINI (Giorgio)`
A11	`05`	`1`		`@1 MESSINA (Chiara)`
A11	`06`	`1`		`@1 YANIV (Isaac)`
A11	`07`	`1`		`@1 FAGIOLI (Franca)`
A11	`08`	`1`		`@1 CASTEL (Victoria)`
A11	`09`	`1`		`@1 SHAW (Peter J.)`
A11	`10`	`1`		`@1 FERRANT (Augustin)`
A11	`11`	`1`		`@1 PESSION (Andrea)`
A11	`12`	`1`		`@1 SOCIE (Gerard)`
A11	`13`	`1`		`@1 FRASSONI (Francesco)`
A14	`01`			`@1 Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Université di Pavia @3 ITA`
A14	`02`			`@1 European Data Management Office @2 Paris @3 FRA`
A14	`03`			`@1 Hospital Matemo Infantil, Vall d'Hebron @2 Barcelona @3 ESP`
A14	`04`			`@1 Dipartimento di Biotecnologie Cellulari ed Ematologia, Université La Sapienza @2 Roma @3 ITA`
A14	`05`			`@1 Dipartimento di Ematologia ed Oncologia, Istituto G. Gaslini @2 Genova @3 ITA`
A14	`06`			`@1 Clinica Pediatrica, Università di Padova @3 ITA`
A14	`07`			`@1 Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel @2 Petach-Tikva @3 ISR`
A14	`08`			`@1 Clinica Pediatrica, Università di Torino @3 ITA`
A14	`09`			`@1 Hospital Infantil La Fe @2 Valencia @3 ESP`
A14	`10`			`@1 Oncology Unit, Children Hospital at Westmead @2 Sydney @3 AUS`
A14	`11`			`@1 Cliniques Universitaires St Luc @2 Brussels @3 BEL`
A14	`12`			`@1 Clinica Pediatrica, Università di Bologna @3 ITA`
A14	`13`			`@1 Department of Hematology, Bone Marrow Transplantation Unit, Hôpital Saint-Louis @2 Paris @3 FRA`
A14	`14`			`@1 Divisione di Ematologia Il, Ospedale San Martino @2 Genova @3 ITA`
A17	`01`	`1`		`@1 European Blood and Marrow Transplantation Acute Leukemia Working Party @3 EUR`
A20				`@1 1611-1619`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 3178 @5 354000104109760550`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 48 ref.`
A47	`01`	`1`		`@0 03-0346488`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Blood`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 To evaluate factors influencing outcome and incidence of long-term complications, we analyzed, in a retrospective, multicenter study, 387 children who underwent autologous hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) in first complete remission (CR). Median follow-up time from transplantation was 60 months. Transplantation of bone marrow cells was performed in 318 children, whereas in 60 patients peripheral blood progenitor cells (PBPCs) were used. In multivariate analysis, we investigated the variables influencing probability of hematopoietic recovery, transplantation-related mortality (TRM), relapse, and leukemia-free survival (LFS). We found that use of PBPCs as stem cell sources and use of BCNU (N,N-bis[2-chloroethyl]-N-nitrosourea), amsacrine, VP-16, and cytosine arabinoside (BAVC) as a preparative regimen were associated with faster neutrophil recovery. Infusion of PBPCs, young age of patients, use of BAVCs, and absence of marrow purging predicted an accelerated platelet reconstitution. The 5-year Kaplan-Meler estimates of TRM, relapse, and LFS were 3% ± 1%, 39% ± 3% and 60% ± 3%, respectively. Relapse probability was increased in children given the BAVC regimen, and it was decreased after In vitro purging of hematopoietic progenitors and in children with a French-American-British classification of M3 and a time Interval of 170 days or more between CR and HSCT. These 2 latter variables favorably Influenced the probability of LFS, which was, by contrast, reduced with the BAVC regimen. Thirty-three percent of patients surviving more than 18 months experienced at least one late sequela; use of total body irradiation was the only predictive factor. The results obtained in this analysis can be of help in designing prospective studies of autologous HSCT in children with AML in first CR.
C02	`01`	`X`		`@0 002B27D02`
C02	`02`	`X`		`@0 002B19B`
C03	`01`	`X`	`FRE`	`@0 Autogreffe @5 01`
C03	`01`	`X`	`ENG`	`@0 Autograft @5 01`
C03	`01`	`X`	`SPA`	`@0 Autoinjerto @5 01`
C03	`02`	`X`	`FRE`	`@0 Greffe @5 02`
C03	`02`	`X`	`ENG`	`@0 Graft @5 02`
C03	`02`	`X`	`SPA`	`@0 Injerto @5 02`
C03	`03`	`X`	`FRE`	`@0 Leucémie myéloblastique @5 04`
C03	`03`	`X`	`ENG`	`@0 Acute myelocytic leukemia @5 04`
C03	`03`	`X`	`SPA`	`@0 Leucemia mieloblástica @5 04`
C03	`04`	`X`	`FRE`	`@0 Etude longitudinale @5 05`
C03	`04`	`X`	`ENG`	`@0 Follow up study @5 05`
C03	`04`	`X`	`SPA`	`@0 Estudio longitudinal @5 05`
C03	`05`	`X`	`FRE`	`@0 Europe @2 NG @5 06`
C03	`05`	`X`	`ENG`	`@0 Europe @2 NG @5 06`
C03	`05`	`X`	`SPA`	`@0 Europa @2 NG @5 06`
C03	`06`	`X`	`FRE`	`@0 Pronostic @5 08`
C03	`06`	`X`	`ENG`	`@0 Prognosis @5 08`
C03	`06`	`X`	`SPA`	`@0 Pronóstico @5 08`
C03	`07`	`X`	`FRE`	`@0 Incidence @5 09`
C03	`07`	`X`	`ENG`	`@0 Incidence @5 09`
C03	`07`	`X`	`SPA`	`@0 Incidencia @5 09`
C03	`08`	`X`	`FRE`	`@0 Long terme @5 11`
C03	`08`	`X`	`ENG`	`@0 Long term @5 11`
C03	`08`	`X`	`SPA`	`@0 Largo plazo @5 11`
C03	`09`	`X`	`FRE`	`@0 Complication @5 12`
C03	`09`	`X`	`ENG`	`@0 Complication @5 12`
C03	`09`	`X`	`SPA`	`@0 Complicación @5 12`
C03	`10`	`X`	`FRE`	`@0 Etude multicentrique @5 13`
C03	`10`	`X`	`ENG`	`@0 Multicenter study @5 13`
C03	`10`	`X`	`SPA`	`@0 Estudio multicéntrico @5 13`
C03	`11`	`X`	`FRE`	`@0 Enfant @5 17`
C03	`11`	`X`	`ENG`	`@0 Child @5 17`
C03	`11`	`X`	`SPA`	`@0 Niño @5 17`
C03	`12`	`X`	`FRE`	`@0 Cellule hématopoïétique @5 18`
C03	`12`	`X`	`ENG`	`@0 Hematopoietic cell @5 18`
C03	`12`	`X`	`SPA`	`@0 Célula hematopoyética @5 18`
C03	`13`	`X`	`FRE`	`@0 Cellule souche @5 19`
C03	`13`	`X`	`ENG`	`@0 Stem cell @5 19`
C03	`13`	`X`	`SPA`	`@0 Célula primitiva @5 19`
C03	`14`	`X`	`FRE`	`@0 Rémission @5 20`
C03	`14`	`X`	`ENG`	`@0 Remission @5 20`
C03	`14`	`X`	`SPA`	`@0 Remisión @5 20`
C03	`15`	`X`	`FRE`	`@0 Santé publique @5 21`
C03	`15`	`X`	`ENG`	`@0 Public health @5 21`
C03	`15`	`X`	`SPA`	`@0 Salud pública @5 21`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
N21				`@1 246`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 03-0346488 INIST
ET :	Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission
AU :	LOCATELLI (Franco); LABOPIN (Myriam); GIOVANNA MELONI (Juan Ortega); DINI (Giorgio); MESSINA (Chiara); YANIV (Isaac); FAGIOLI (Franca); CASTEL (Victoria); SHAW (Peter J.); FERRANT (Augustin); PESSION (Andrea); SOCIE (Gerard); FRASSONI (Francesco)
AF :	Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Université di Pavia/Italie; European Data Management Office/Paris/France; Hospital Matemo Infantil, Vall d'Hebron/Barcelona/Espagne; Dipartimento di Biotecnologie Cellulari ed Ematologia, Université La Sapienza/Roma/Italie; Dipartimento di Ematologia ed Oncologia, Istituto G. Gaslini/Genova/Italie; Clinica Pediatrica, Università di Padova/Italie; Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel/Petach-Tikva/Israël; Clinica Pediatrica, Università di Torino/Italie; Hospital Infantil La Fe/Valencia/Espagne; Oncology Unit, Children Hospital at Westmead/Sydney/Australie; Cliniques Universitaires St Luc/Brussels/Belgique; Clinica Pediatrica, Università di Bologna/Italie; Department of Hematology, Bone Marrow Transplantation Unit, Hôpital Saint-Louis/Paris/France; Divisione di Ematologia Il, Ospedale San Martino/Genova/Italie
DT :	Publication en série; Niveau analytique
SO :	Blood; ISSN 0006-4971; Etats-Unis; Da. 2003; Vol. 101; No. 4; Pp. 1611-1619; Bibl. 48 ref.
LA :	Anglais
EA :	To evaluate factors influencing outcome and incidence of long-term complications, we analyzed, in a retrospective, multicenter study, 387 children who underwent autologous hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) in first complete remission (CR). Median follow-up time from transplantation was 60 months. Transplantation of bone marrow cells was performed in 318 children, whereas in 60 patients peripheral blood progenitor cells (PBPCs) were used. In multivariate analysis, we investigated the variables influencing probability of hematopoietic recovery, transplantation-related mortality (TRM), relapse, and leukemia-free survival (LFS). We found that use of PBPCs as stem cell sources and use of BCNU (N,N-bis[2-chloroethyl]-N-nitrosourea), amsacrine, VP-16, and cytosine arabinoside (BAVC) as a preparative regimen were associated with faster neutrophil recovery. Infusion of PBPCs, young age of patients, use of BAVCs, and absence of marrow purging predicted an accelerated platelet reconstitution. The 5-year Kaplan-Meler estimates of TRM, relapse, and LFS were 3% ± 1%, 39% ± 3% and 60% ± 3%, respectively. Relapse probability was increased in children given the BAVC regimen, and it was decreased after In vitro purging of hematopoietic progenitors and in children with a French-American-British classification of M3 and a time Interval of 170 days or more between CR and HSCT. These 2 latter variables favorably Influenced the probability of LFS, which was, by contrast, reduced with the BAVC regimen. Thirty-three percent of patients surviving more than 18 months experienced at least one late sequela; use of total body irradiation was the only predictive factor. The results obtained in this analysis can be of help in designing prospective studies of autologous HSCT in children with AML in first CR.
CC :	002B27D02; 002B19B
FD :	Autogreffe; Greffe; Leucémie myéloblastique; Etude longitudinale; Europe; Pronostic; Incidence; Long terme; Complication; Etude multicentrique; Enfant; Cellule hématopoïétique; Cellule souche; Rémission; Santé publique
FG :	Homme
ED :	Autograft; Graft; Acute myelocytic leukemia; Follow up study; Europe; Prognosis; Incidence; Long term; Complication; Multicenter study; Child; Hematopoietic cell; Stem cell; Remission; Public health
EG :	Human
SD :	Autoinjerto; Injerto; Leucemia mieloblástica; Estudio longitudinal; Europa; Pronóstico; Incidencia; Largo plazo; Complicación; Estudio multicéntrico; Niño; Célula hematopoyética; Célula primitiva; Remisión; Salud pública
LO :	INIST-3178.354000104109760550
ID :	03-0346488

Links to Exploration step

Pascal:03-0346488

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission</title>
<author><name sortKey="Locatelli, Franco" sort="Locatelli, Franco" uniqKey="Locatelli F" first="Franco" last="Locatelli">Franco Locatelli</name>
<affiliation><inist:fA14 i1="01"><s1>Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Université di Pavia</s1>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>European Data Management Office</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Hospital Matemo Infantil, Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Dipartimento di Biotecnologie Cellulari ed Ematologia, Université La Sapienza</s1>
<s2>Roma</s2>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Dipartimento di Ematologia ed Oncologia, Istituto G. Gaslini</s1>
<s2>Genova</s2>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Clinica Pediatrica, Università di Padova</s1>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel</s1>
<s2>Petach-Tikva</s2>
<s3>ISR</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="08"><s1>Clinica Pediatrica, Università di Torino</s1>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="09"><s1>Hospital Infantil La Fe</s1>
<s2>Valencia</s2>
<s3>ESP</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="10"><s1>Oncology Unit, Children Hospital at Westmead</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="11"><s1>Cliniques Universitaires St Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="12"><s1>Clinica Pediatrica, Università di Bologna</s1>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="13"><s1>Department of Hematology, Bone Marrow Transplantation Unit, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="14"><s1>Divisione di Ematologia Il, Ospedale San Martino</s1>
<s2>Genova</s2>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Labopin, Myriam" sort="Labopin, Myriam" uniqKey="Labopin M" first="Myriam" last="Labopin">Myriam Labopin</name>
</author>
<author><name sortKey="Giovanna Meloni, Juan Ortega" sort="Giovanna Meloni, Juan Ortega" uniqKey="Giovanna Meloni J" first="Juan Ortega" last="Giovanna Meloni">Juan Ortega Giovanna Meloni</name>
</author>
<author><name sortKey="Dini, Giorgio" sort="Dini, Giorgio" uniqKey="Dini G" first="Giorgio" last="Dini">Giorgio Dini</name>
</author>
<author><name sortKey="Messina, Chiara" sort="Messina, Chiara" uniqKey="Messina C" first="Chiara" last="Messina">Chiara Messina</name>
</author>
<author><name sortKey="Yaniv, Isaac" sort="Yaniv, Isaac" uniqKey="Yaniv I" first="Isaac" last="Yaniv">Isaac Yaniv</name>
</author>
<author><name sortKey="Fagioli, Franca" sort="Fagioli, Franca" uniqKey="Fagioli F" first="Franca" last="Fagioli">Franca Fagioli</name>
</author>
<author><name sortKey="Castel, Victoria" sort="Castel, Victoria" uniqKey="Castel V" first="Victoria" last="Castel">Victoria Castel</name>
</author>
<author><name sortKey="Shaw, Peter J" sort="Shaw, Peter J" uniqKey="Shaw P" first="Peter J." last="Shaw">Peter J. Shaw</name>
</author>
<author><name sortKey="Ferrant, Augustin" sort="Ferrant, Augustin" uniqKey="Ferrant A" first="Augustin" last="Ferrant">Augustin Ferrant</name>
</author>
<author><name sortKey="Pession, Andrea" sort="Pession, Andrea" uniqKey="Pession A" first="Andrea" last="Pession">Andrea Pession</name>
</author>
<author><name sortKey="Socie, Gerard" sort="Socie, Gerard" uniqKey="Socie G" first="Gerard" last="Socie">Gerard Socie</name>
</author>
<author><name sortKey="Frassoni, Francesco" sort="Frassoni, Francesco" uniqKey="Frassoni F" first="Francesco" last="Frassoni">Francesco Frassoni</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0346488</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0346488 INIST</idno>
<idno type="RBID">Pascal:03-0346488</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">005302</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission</title>
<author><name sortKey="Locatelli, Franco" sort="Locatelli, Franco" uniqKey="Locatelli F" first="Franco" last="Locatelli">Franco Locatelli</name>
<affiliation><inist:fA14 i1="01"><s1>Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Université di Pavia</s1>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>European Data Management Office</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Hospital Matemo Infantil, Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Dipartimento di Biotecnologie Cellulari ed Ematologia, Université La Sapienza</s1>
<s2>Roma</s2>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Dipartimento di Ematologia ed Oncologia, Istituto G. Gaslini</s1>
<s2>Genova</s2>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Clinica Pediatrica, Università di Padova</s1>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel</s1>
<s2>Petach-Tikva</s2>
<s3>ISR</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="08"><s1>Clinica Pediatrica, Università di Torino</s1>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="09"><s1>Hospital Infantil La Fe</s1>
<s2>Valencia</s2>
<s3>ESP</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="10"><s1>Oncology Unit, Children Hospital at Westmead</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="11"><s1>Cliniques Universitaires St Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="12"><s1>Clinica Pediatrica, Università di Bologna</s1>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="13"><s1>Department of Hematology, Bone Marrow Transplantation Unit, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="14"><s1>Divisione di Ematologia Il, Ospedale San Martino</s1>
<s2>Genova</s2>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Labopin, Myriam" sort="Labopin, Myriam" uniqKey="Labopin M" first="Myriam" last="Labopin">Myriam Labopin</name>
</author>
<author><name sortKey="Giovanna Meloni, Juan Ortega" sort="Giovanna Meloni, Juan Ortega" uniqKey="Giovanna Meloni J" first="Juan Ortega" last="Giovanna Meloni">Juan Ortega Giovanna Meloni</name>
</author>
<author><name sortKey="Dini, Giorgio" sort="Dini, Giorgio" uniqKey="Dini G" first="Giorgio" last="Dini">Giorgio Dini</name>
</author>
<author><name sortKey="Messina, Chiara" sort="Messina, Chiara" uniqKey="Messina C" first="Chiara" last="Messina">Chiara Messina</name>
</author>
<author><name sortKey="Yaniv, Isaac" sort="Yaniv, Isaac" uniqKey="Yaniv I" first="Isaac" last="Yaniv">Isaac Yaniv</name>
</author>
<author><name sortKey="Fagioli, Franca" sort="Fagioli, Franca" uniqKey="Fagioli F" first="Franca" last="Fagioli">Franca Fagioli</name>
</author>
<author><name sortKey="Castel, Victoria" sort="Castel, Victoria" uniqKey="Castel V" first="Victoria" last="Castel">Victoria Castel</name>
</author>
<author><name sortKey="Shaw, Peter J" sort="Shaw, Peter J" uniqKey="Shaw P" first="Peter J." last="Shaw">Peter J. Shaw</name>
</author>
<author><name sortKey="Ferrant, Augustin" sort="Ferrant, Augustin" uniqKey="Ferrant A" first="Augustin" last="Ferrant">Augustin Ferrant</name>
</author>
<author><name sortKey="Pession, Andrea" sort="Pession, Andrea" uniqKey="Pession A" first="Andrea" last="Pession">Andrea Pession</name>
</author>
<author><name sortKey="Socie, Gerard" sort="Socie, Gerard" uniqKey="Socie G" first="Gerard" last="Socie">Gerard Socie</name>
</author>
<author><name sortKey="Frassoni, Francesco" sort="Frassoni, Francesco" uniqKey="Frassoni F" first="Francesco" last="Frassoni">Francesco Frassoni</name>
</author>
</analytic>
<series><title level="j" type="main">Blood</title>
<title level="j" type="abbreviated">Blood</title>
<idno type="ISSN">0006-4971</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Blood</title>
<title level="j" type="abbreviated">Blood</title>
<idno type="ISSN">0006-4971</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute myelocytic leukemia</term>
<term>Autograft</term>
<term>Child</term>
<term>Complication</term>
<term>Europe</term>
<term>Follow up study</term>
<term>Graft</term>
<term>Hematopoietic cell</term>
<term>Incidence</term>
<term>Long term</term>
<term>Multicenter study</term>
<term>Prognosis</term>
<term>Public health</term>
<term>Remission</term>
<term>Stem cell</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Autogreffe</term>
<term>Greffe</term>
<term>Leucémie myéloblastique</term>
<term>Etude longitudinale</term>
<term>Europe</term>
<term>Pronostic</term>
<term>Incidence</term>
<term>Long terme</term>
<term>Complication</term>
<term>Etude multicentrique</term>
<term>Enfant</term>
<term>Cellule hématopoïétique</term>
<term>Cellule souche</term>
<term>Rémission</term>
<term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To evaluate factors influencing outcome and incidence of long-term complications, we analyzed, in a retrospective, multicenter study, 387 children who underwent autologous hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) in first complete remission (CR). Median follow-up time from transplantation was 60 months. Transplantation of bone marrow cells was performed in 318 children, whereas in 60 patients peripheral blood progenitor cells (PBPCs) were used. In multivariate analysis, we investigated the variables influencing probability of hematopoietic recovery, transplantation-related mortality (TRM), relapse, and leukemia-free survival (LFS). We found that use of PBPCs as stem cell sources and use of BCNU (N,N-bis[2-chloroethyl]-N-nitrosourea), amsacrine, VP-16, and cytosine arabinoside (BAVC) as a preparative regimen were associated with faster neutrophil recovery. Infusion of PBPCs, young age of patients, use of BAVCs, and absence of marrow purging predicted an accelerated platelet reconstitution. The 5-year Kaplan-Meler estimates of TRM, relapse, and LFS were 3% ± 1%, 39% ± 3% and 60% ± 3%, respectively. Relapse probability was increased in children given the BAVC regimen, and it was decreased after In vitro purging of hematopoietic progenitors and in children with a French-American-British classification of M3 and a time Interval of 170 days or more between CR and HSCT. These 2 latter variables favorably Influenced the probability of LFS, which was, by contrast, reduced with the BAVC regimen. Thirty-three percent of patients surviving more than 18 months experienced at least one late sequela; use of total body irradiation was the only predictive factor. The results obtained in this analysis can be of help in designing prospective studies of autologous HSCT in children with AML in first CR.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-4971</s0>
</fA01>
<fA03 i2="1"><s0>Blood</s0>
</fA03>
<fA05><s2>101</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LOCATELLI (Franco)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LABOPIN (Myriam)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GIOVANNA MELONI (Juan Ortega)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DINI (Giorgio)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MESSINA (Chiara)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>YANIV (Isaac)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FAGIOLI (Franca)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>CASTEL (Victoria)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SHAW (Peter J.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>FERRANT (Augustin)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>PESSION (Andrea)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SOCIE (Gerard)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>FRASSONI (Francesco)</s1>
</fA11>
<fA14 i1="01"><s1>Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Université di Pavia</s1>
<s3>ITA</s3>
</fA14>
<fA14 i1="02"><s1>European Data Management Office</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="03"><s1>Hospital Matemo Infantil, Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
</fA14>
<fA14 i1="04"><s1>Dipartimento di Biotecnologie Cellulari ed Ematologia, Université La Sapienza</s1>
<s2>Roma</s2>
<s3>ITA</s3>
</fA14>
<fA14 i1="05"><s1>Dipartimento di Ematologia ed Oncologia, Istituto G. Gaslini</s1>
<s2>Genova</s2>
<s3>ITA</s3>
</fA14>
<fA14 i1="06"><s1>Clinica Pediatrica, Università di Padova</s1>
<s3>ITA</s3>
</fA14>
<fA14 i1="07"><s1>Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel</s1>
<s2>Petach-Tikva</s2>
<s3>ISR</s3>
</fA14>
<fA14 i1="08"><s1>Clinica Pediatrica, Università di Torino</s1>
<s3>ITA</s3>
</fA14>
<fA14 i1="09"><s1>Hospital Infantil La Fe</s1>
<s2>Valencia</s2>
<s3>ESP</s3>
</fA14>
<fA14 i1="10"><s1>Oncology Unit, Children Hospital at Westmead</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
</fA14>
<fA14 i1="11"><s1>Cliniques Universitaires St Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
</fA14>
<fA14 i1="12"><s1>Clinica Pediatrica, Università di Bologna</s1>
<s3>ITA</s3>
</fA14>
<fA14 i1="13"><s1>Department of Hematology, Bone Marrow Transplantation Unit, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="14"><s1>Divisione di Ematologia Il, Ospedale San Martino</s1>
<s2>Genova</s2>
<s3>ITA</s3>
</fA14>
<fA17 i1="01" i2="1"><s1>European Blood and Marrow Transplantation Acute Leukemia Working Party</s1>
<s3>EUR</s3>
</fA17>
<fA20><s1>1611-1619</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3178</s2>
<s5>354000104109760550</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>48 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0346488</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Blood</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To evaluate factors influencing outcome and incidence of long-term complications, we analyzed, in a retrospective, multicenter study, 387 children who underwent autologous hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) in first complete remission (CR). Median follow-up time from transplantation was 60 months. Transplantation of bone marrow cells was performed in 318 children, whereas in 60 patients peripheral blood progenitor cells (PBPCs) were used. In multivariate analysis, we investigated the variables influencing probability of hematopoietic recovery, transplantation-related mortality (TRM), relapse, and leukemia-free survival (LFS). We found that use of PBPCs as stem cell sources and use of BCNU (N,N-bis[2-chloroethyl]-N-nitrosourea), amsacrine, VP-16, and cytosine arabinoside (BAVC) as a preparative regimen were associated with faster neutrophil recovery. Infusion of PBPCs, young age of patients, use of BAVCs, and absence of marrow purging predicted an accelerated platelet reconstitution. The 5-year Kaplan-Meler estimates of TRM, relapse, and LFS were 3% ± 1%, 39% ± 3% and 60% ± 3%, respectively. Relapse probability was increased in children given the BAVC regimen, and it was decreased after In vitro purging of hematopoietic progenitors and in children with a French-American-British classification of M3 and a time Interval of 170 days or more between CR and HSCT. These 2 latter variables favorably Influenced the probability of LFS, which was, by contrast, reduced with the BAVC regimen. Thirty-three percent of patients surviving more than 18 months experienced at least one late sequela; use of total body irradiation was the only predictive factor. The results obtained in this analysis can be of help in designing prospective studies of autologous HSCT in children with AML in first CR.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B27D02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B19B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Autogreffe</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Autograft</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Autoinjerto</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Greffe</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Graft</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Injerto</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Leucémie myéloblastique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Acute myelocytic leukemia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Leucemia mieloblástica</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etude longitudinale</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Follow up study</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estudio longitudinal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Incidence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Incidence</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Incidencia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Long terme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Long term</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Complication</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Complication</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Complicación</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Enfant</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Child</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Niño</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Cellule hématopoïétique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Hematopoietic cell</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Célula hematopoyética</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Cellule souche</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Stem cell</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Célula primitiva</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Rémission</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Remission</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Remisión</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Public health</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fN21><s1>246</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 03-0346488 INIST</NO>
<ET>Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission</ET>
<AU>LOCATELLI (Franco); LABOPIN (Myriam); GIOVANNA MELONI (Juan Ortega); DINI (Giorgio); MESSINA (Chiara); YANIV (Isaac); FAGIOLI (Franca); CASTEL (Victoria); SHAW (Peter J.); FERRANT (Augustin); PESSION (Andrea); SOCIE (Gerard); FRASSONI (Francesco)</AU>
<AF>Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Université di Pavia/Italie; European Data Management Office/Paris/France; Hospital Matemo Infantil, Vall d'Hebron/Barcelona/Espagne; Dipartimento di Biotecnologie Cellulari ed Ematologia, Université La Sapienza/Roma/Italie; Dipartimento di Ematologia ed Oncologia, Istituto G. Gaslini/Genova/Italie; Clinica Pediatrica, Università di Padova/Italie; Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel/Petach-Tikva/Israël; Clinica Pediatrica, Università di Torino/Italie; Hospital Infantil La Fe/Valencia/Espagne; Oncology Unit, Children Hospital at Westmead/Sydney/Australie; Cliniques Universitaires St Luc/Brussels/Belgique; Clinica Pediatrica, Università di Bologna/Italie; Department of Hematology, Bone Marrow Transplantation Unit, Hôpital Saint-Louis/Paris/France; Divisione di Ematologia Il, Ospedale San Martino/Genova/Italie</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Blood; ISSN 0006-4971; Etats-Unis; Da. 2003; Vol. 101; No. 4; Pp. 1611-1619; Bibl. 48 ref.</SO>
<LA>Anglais</LA>
<EA>To evaluate factors influencing outcome and incidence of long-term complications, we analyzed, in a retrospective, multicenter study, 387 children who underwent autologous hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) in first complete remission (CR). Median follow-up time from transplantation was 60 months. Transplantation of bone marrow cells was performed in 318 children, whereas in 60 patients peripheral blood progenitor cells (PBPCs) were used. In multivariate analysis, we investigated the variables influencing probability of hematopoietic recovery, transplantation-related mortality (TRM), relapse, and leukemia-free survival (LFS). We found that use of PBPCs as stem cell sources and use of BCNU (N,N-bis[2-chloroethyl]-N-nitrosourea), amsacrine, VP-16, and cytosine arabinoside (BAVC) as a preparative regimen were associated with faster neutrophil recovery. Infusion of PBPCs, young age of patients, use of BAVCs, and absence of marrow purging predicted an accelerated platelet reconstitution. The 5-year Kaplan-Meler estimates of TRM, relapse, and LFS were 3% ± 1%, 39% ± 3% and 60% ± 3%, respectively. Relapse probability was increased in children given the BAVC regimen, and it was decreased after In vitro purging of hematopoietic progenitors and in children with a French-American-British classification of M3 and a time Interval of 170 days or more between CR and HSCT. These 2 latter variables favorably Influenced the probability of LFS, which was, by contrast, reduced with the BAVC regimen. Thirty-three percent of patients surviving more than 18 months experienced at least one late sequela; use of total body irradiation was the only predictive factor. The results obtained in this analysis can be of help in designing prospective studies of autologous HSCT in children with AML in first CR.</EA>
<CC>002B27D02; 002B19B</CC>
<FD>Autogreffe; Greffe; Leucémie myéloblastique; Etude longitudinale; Europe; Pronostic; Incidence; Long terme; Complication; Etude multicentrique; Enfant; Cellule hématopoïétique; Cellule souche; Rémission; Santé publique</FD>
<FG>Homme</FG>
<ED>Autograft; Graft; Acute myelocytic leukemia; Follow up study; Europe; Prognosis; Incidence; Long term; Complication; Multicenter study; Child; Hematopoietic cell; Stem cell; Remission; Public health</ED>
<EG>Human</EG>
<SD>Autoinjerto; Injerto; Leucemia mieloblástica; Estudio longitudinal; Europa; Pronóstico; Incidencia; Largo plazo; Complicación; Estudio multicéntrico; Niño; Célula hematopoyética; Célula primitiva; Remisión; Salud pública</SD>
<LO>INIST-3178.354000104109760550</LO>
<ID>03-0346488</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005302 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 005302 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:03-0346488
   |texte=   Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission

Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri